Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Press releaseGlobeNewswire· April 13, 2026

XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset

View original at globenewswire.com

XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset • VB4-P5 – novel new chemical entity with potential to address significant unmet need in rare and large-market chronic kidney disease • CALGARY, Alberta, April 13, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc…

Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

The addressable market for kidney disease treatment is estimated to exceed 10 million individuals
60% confidence
VB4-P5 has the potential to be a new treatment for mid-late stage chronic kidney disease, slow kidney disease progression and accompanying fibrosis
60% confidence
VB4-P5 program is directly aligned with XORTX's strategic focus on developing innovative therapies to treat individuals with progressive kidney disease and broadens pipeline with a new technological direction
60% confidence
No currently approved therapies specifically target or reverse kidney fibrosis
60% confidence
Early preclinical data from the VB4-P5 program demonstrate the potential of this potent small molecule to inhibit and possibly reverse kidney fibrosis
60% confidence

Cited in these Via News reports

FDA Fast-Tracks Lung Cancer Drug as Biotech Sector Logs $430M in Deals →